A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

By afschroeder • July 31, 2026

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig MB, Vassy JL, Garraway IP, Iyer HS. A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program. Cancer Epidemiol Biomarkers Prev. 2026 Jul 30. doi: 10.1158/1055-9965.EPI-26-0248. Epub ahead of print. PMID: 42530444.

Tags: Hematology/Oncology, Publications, Veterans Administration

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

Li YR, Zhu Y, Yu Y, Kramer A, Shao Z, Chen Y, Shen X, Zhang C, Ma N, Zhao A, Ochoa CJ, DiBernardo GA, Yuen[...]

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]